Analysis of influencing factors of the degree of increase in serum uric acid in patients with pyrazinamide-related hyperuricemia
10.3760/cma.j.cn114015-20191225-01067
- VernacularTitle:吡嗪酰胺相关高尿酸血症患者血尿酸升高程度的影响因素分析
- Author:
Shuo LIU
1
;
Wanli KANG
;
Rui XU
;
Jing ZHANG
;
Xinfeng MAO
;
Kai CHENG
Author Information
1. 首都医科大学附属北京胸科医院药学部，北京 101149
- Publication Type:Journal Article
- Keywords:
Tuberculosis;
Pyrazinamide;
Hyperuricemia;
Factor analysis, statistical;
Drug-related side effects and adverse reactions
- From:
Adverse Drug Reactions Journal
2020;22(12):665-669
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To analyze the influencing factors of the degree of increase in serum uric acid in patients with hyperuricemia related to pyrazinamide.Methods:The National ADR Monitoring Information Network System was searched and the adverse reaction reports of hyperuricemia induced by pyrazinamide that were reported from January 2012 to June 2019 in Beijing Chest Hospital, Capital Medical University were collected. The patients' gender, age, height, weight, history of drug allergy, antituberculosis therapy, time of pyrazinamide treatment, and serum uric acid level before and after the treatment were recorded. Linear regression method was used to analyze the influence of the above factors on the degree of increase in serum uric acid, which was expressed by the change rate of serum uric acid.Results:A total of 177 patients were enrolled in the study, including 124 males and 53 females; their ages were from 15 to 82 years, with a median age of 33 (23, 54) years; their body weight was (60±12) kg, in which 34 cases (19.2%) were <50 kg, 123 cases (69.5%) were 50-75 kg, and 20 cases (11.3%) were >75 kg; their height was (170±8) cm. Among the 177 patients, 143 cases (80.8%) received first-line regimen and 34 cases (19.2%) received second-line regimen; the time of pyrazinamide treatment was 1 to 97 days, with a median time of 8 (6, 11) days; 33 cases (18.6%) had history of drug allergy. The baseline uric acid level in 177 patients was (288±72) μmol/L before pyrazinamide administration and (640±105) μmol/L when hyperuricemia occurred. The change rate of serum uric acid was (139±82)%. Univariate linear regression analysis showed that body weight was negatively correlated with the change rate of serum uric acid ( r=-1.343, t=-2.660, P=0.009). The difference in the change rate of serum uric acid among patients with different body weight was statistically significant ( χ 2=6.977, P=0.031). The difference in the change rate of serum uric acid between the <50 kg group and the >75 kg group was statistically significant ( Z=-2.544, P=0.011). Conclusions:Body weight is an independent influencing factor for the degree of increase in serum uric acid in patients with hyperuricemia related to pyrazinamide. The change rate of serum uric acid in hyperuricemia patients with lower body weight is higher.
